French Society of Dermatology 2025 guideline update for adults with moderate-to-severe psoriasis recommends methotrexate, adalimumab or ustekinumab as first systemic treatment when there are no symptomatic comorbidities, with algorithms for later management.
Guideline
Masson Regnault et al. French guidelines on systemic treatments for moderate-to-severe psoriasis in adults: Update 2025